Key facts
- Celestial Therapeutics’s last known valuation is $10.2M (Dec 2020).
- It has raised $2.4M across 2 recorded rounds; the latest was Seed Round ($800K) in Sep 2024.
- Notable investors include National Institutes of Health, StartX (US), Endless Frontier Labs, CONNECT (San Diego), Johnson & Johnson Innovation - JLABS — 7 tracked in total.
- Celestial Therapeutics has filed 32 Form Ds with the SEC since 2020, most recently Oct 2025 ($800K sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Celestial Therapeutics
Funding rounds
2 roundsAbout Celestial Therapeutics
Operator of a biotechnology company designed to develop therapies that treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company offers proprietary lipid and mRNA technology platforms, leveraging innate immunity and nature-inspired science, enabling patients with hard-to-treat diseases to achieve improved therapeutic outcomes.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 5
- Website
- celestialtherapeutics.com/
- Ownership
- Privately Held (backing)
Celestial Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celestial Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celestial Therapeutics in its N-PORT filings yet. We sweep new filings monthly.